Vidal suggests tougher scrutiny for pharma patents is in the works
In some of her first public remarks, USPTO director hints at concrete actions the agency could soon take to address perceived patent abuses in life sciences
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.